US FDA Awards Orphan Drug Designation (OOD) to Paxalisib for AT/RT, a Rare Form of Childhood Brain Cancer

Kazia Therapeutics Limited announced that the US FDA has awarded ODD to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors, a rare and highly aggressive childhood brain cancer.
[Kazia Therapeutics Limited]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News